Purpose The Treatment exit Options For non-infectious Uveitis (TOFU) registry documents disease courses for non-anterior non-infectious uveitis entities with and without treatment to generate more evidence for clinical management recommendations including treatment exit strategies. In this article, we present the participants’ baseline characteristics after the first 3 years. Methods TOFU is an observational, prospective registry and recruits patients ≥18 years of age with non-anterior non-infectious uveitis with or without a history of previous disease-modifying antirheumatic drugs (DMARDs) treatment. The data are collected in the electronic data capture software REDCap and include ophthalmological and general medical history as well as clinical findings. Results Between 24.10.2019 and 27.12.2022, 628 patients were enrolled at 25 clinical sites in Germany and Austria. Patients with intermediate uveitis were most frequently included (n=252; 40.1%) followed by posterior uveitis (181; 28.8%), panuveitis (n=154; 24.5%) and retinal vasculitis (n=41, 6.5%). At baseline, 39.6% were treated with systemic corticosteroids, 22.3% with conventional synthetic (cs) DMARDs, 20.5% with biological (b) DMARDs and 3.6% with other systemic treatments. Average best corrected visual acuity (BCVA) was 0.69 decimal. Patients with panuveitis had the worst BCVA with 0.63 decimal. Overall, only 8 patients (1.3%) suffered from severe visual impairment. Conclusions Less than half of participants required DMARD treatment at baseline, with csDMARDs used more frequently than bDMARDs. The presence of severe visual impairment was low, mostly affecting patients with panuveitis. These findings are in line with comparable monocentric cross-sectional studies of tertiary uveitis centres in Germany and will allow us to generate generalisable evidence in TOFU. Data are available upon reasonable request. The raw data that support the findings of this study are available from the corresponding author (RPF) upon reasonable request and discussion with the authors. Data are located in controlled access data storage at the Department of Medical Biometry, Informatics and Epidemiology (IMBIE), Bonn, Germany.

中文翻译：

---

非感染性葡萄膜炎登记的治疗退出选择：3 岁时的参与者特征


目的：治疗退出选择：对于非感染性葡萄膜炎 （TOFU） 登记处，记录非前部非感染性葡萄膜炎实体的病程，接受治疗和不接受治疗，为临床管理建议（包括治疗退出策略）生成更多证据。在本文中，我们介绍了参与者在前 3 年后的基线特征。方法 TOFU 是一项观察性、前瞻性登记，招募 ≥18 岁患有非前部非感染性葡萄膜炎的患者，有或没有既往疾病缓解抗风湿药 （DMARDs） 治疗史。数据收集在电子数据采集软件 REDCap 中，包括眼科和一般病史以及临床发现。结果 2019 年 10 月 24 日至 2022 年 12 月 27 日期间，在德国和奥地利的 25 个临床地点招募了 628 名患者。中间葡萄膜炎患者最常被纳入 （n=252;40.1%），其次是后葡萄膜炎 （181;28.8%）、全葡萄膜炎 （n=154;24.5%） 和视网膜血管炎 （n=41， 6.5%）。基线时，39.6% 接受全身性皮质类固醇治疗，22.3% 接受常规合成 （cs） DMARDs，20.5% 接受生物 （b） DMARDs，3.6% 接受其他全身治疗。平均最佳矫正视力 （BCVA） 为小数点后 0.69 分。全葡萄膜炎患者的 BCVA 最差，小数点后为 0.63。总体而言，只有 8 例患者 （1.3%） 患有严重视力障碍。结论 不到一半的参与者在基线时需要 DMARD 治疗，csDMARD 的使用频率高于 bDMARD。严重视力损害的存在率较低，主要影响全葡萄膜炎患者。 这些发现与德国三级葡萄膜炎中心的可比单中心横断面研究一致，将使我们能够在 TOFU 中产生可推广的证据。数据可根据合理要求提供。支持本研究结果的原始数据可在合理要求并与作者讨论后从通讯作者 （RPF） 处获得。数据位于德国波恩医学生物统计学、信息学和流行病学系 （IMBIE） 的受控访问数据存储中。